Development

Vironexis reports early durable ALL responses with one-time AAV therapy

Vironexis reports early durable ALL responses with one-time AAV therapy

Early Phase I/II data from San Diego-based Vironexis Biotherapeutics show that a single dose of an adeno-associated virus (AAV)-based gene therapy can produce measurable residual disease (MRD)-negative complete responses in patients with relapsed or refractory acute lymphoblastic leukemia (ALL) — and sustain them for months without repeat dosing. The finding, reported September 21, provide an early clinical signal that a systemically delivered, one-time in vivo gene therapy can generate durable antitumor activity in blood cancer patients, including those with extramedullary disease.

All three anti-AAV antibody-naive R/R ALL patients enrolled in the SENTRY-CD19 study achieved MRD-negative complete responses after a single infusion of VNX-101, confirmed by clonoSEQ. One patient with extensive extramedullary disease achieved complete responses at all disease sites on PET imaging within 28 days. All three patients remain MRD-negative, with the first patient maintaining complete response through Day 260 before proceeding to hematopoietic stem cell transplantation. The T-cell-engaging protein GP101 was still detectable at therapeutic levels post-transplant, demonstrating persistence of at least nine months following a single administration. Immune-mediated adverse events, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), were observed during dose escalation but resolved with standard of care. Vironexis said the safety profile is informing ongoing dose optimization.

VNX-101 works by delivering an AAV vector that transduces hepatocytes to continuously secrete GP101, a CD19×CD3 bispecific T-cell engager that simultaneously binds CD19-positive cancer cells and CD3-expressing T cells, redirecting cytotoxic T cells to kill tumor cells. The approach is designed to combine the pharmacology of a bispecific T-cell engager with the convenience of a single administration.

Nine patients have been dosed across the broader SENTRY-CD19 study, spanning ALL, diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia. Vironexis said it intends to prioritize development in antibody-naive R/R ALL based on the emerging clinical profile.

The AllSci BriefFree, systematic R&D and deal news. Daily.

The competitive context for VNX-101 in R/R ALL is defined by two distinct therapeutic modalities. Amgen's Blincyto (blinatumomab), the only approved CD19×CD3 bispecific T-cell engager, shares the same pharmacological mechanism as GP101 but requires continuous intravenous infusion over 28-day cycles — a logistical burden VNX-101 is designed to eliminate. Autologous CAR-T therapies — including Kite Pharma's Tecartus (brexucabtagene autoleucel), Novartis's Kymriah (tisagenlecleucel), and Autolus's Aucatzyl (obecabtagene autoleucel) — can produce durable responses after a single infusion, but require individualized ex vivo manufacturing that typically takes three to six weeks, a critical constraint in rapidly progressing R/R ALL. VNX-101's off-the-shelf availability - the molecule is pre-manufactured/systemically administered approach - could address this access gap, though the current dataset of three antibody-naive ALL patients is too small to draw comparative conclusions.

VNX-101 holds FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations. When Vironexis emerged from stealth in September 2024 with USD 26 million in seed financing, the company described VNX-101 as the first AAV-delivered cancer immunotherapy to enter clinical testing. Vironexis also announced the appointment of former Amgen chief executive Kevin Sharer as chairman of its board and Nobel laureate James Allison to its scientific advisory board. The company's second program, VNX-202, is enrolling patients in a Phase I/II study targeting HER2-positive malignancies.


Access the AllSci platform to explore the science behind the news.


Spot something wrong? Report an issue with this article